NCT00554619View on ClinicalTrials.gov

A Study to Evaluate GSK1325760A - a Long-Term Extension Study

PHASE3CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

January 31, 2011

Study Completion Date

January 31, 2011

Conditions
Pulmonary Arterial HypertensionHypertension, Pulmonary
Interventions
DRUG

GSK1325760A

2.5mg, 5mg or 10mg/day, po, GSK1325760A treatment will be continued until its approval by the MHLW.

Trial Locations (11)

470-1192

GSK Investigational Site, Aichi

060-8543

GSK Investigational Site, Hokkaido

060-8648

GSK Investigational Site, Hokkaido

920-8641

GSK Investigational Site, Ishikawa

252-0375

GSK Investigational Site, Kanagawa

606-8507

GSK Investigational Site, Kyoto

701-1192

GSK Investigational Site, Okayama

901-0243

GSK Investigational Site, Okinawa

565-8565

GSK Investigational Site, Osaka

113-8655

GSK Investigational Site, Tokyo

160-8582

GSK Investigational Site, Tokyo

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00554619 - A Study to Evaluate GSK1325760A - a Long-Term Extension Study | Biotech Hunter | Biotech Hunter